Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Vaxcyte, Inc., PCVX
Summary: Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.
- Last Price: $62.54
- Price Change: $-1.97, -3.05%
- Yearly Gain: 72.71%
- Market Cap: $6.78B
- P/E Ratio: -15.11
Here are 3rd party ratings for PCVX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Vaxcyte, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in PCVX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PCVX before you decide to make any investment.
Click here for chart >>
Celldex Therapeutics, Inc., CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $39.19
- Price Change: $-1.43, -3.52%
- Yearly Gain: 24.41%
- Market Cap: $2.52B
- P/E Ratio: -13.42
Here are 3rd party ratings for CLDX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Celldex Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
Alphatec Holdings, Inc., ATEC
Summary: Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California.
- Last Price: $14.13
- Price Change: $-0.13, -0.91%
- Yearly Gain: -11.36%
- Market Cap: $1.95B
- P/E Ratio: -9.18
Here are 3rd party ratings for ATEC:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 37% (93 out of 252)
What is the sentiment on the street regarding Alphatec Holdings, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in ATEC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ATEC before you decide to make any investment.
Click here for chart >>
Catalyst Pharmaceuticals, Inc., CPRX
Summary: Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
- Last Price: $15.88
- Price Change: $0.09, 0.57%
- Yearly Gain: -8.00%
- Market Cap: $1.87B
- P/E Ratio: 25.21
Here are 3rd party ratings for CPRX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Bottom 41% (149 out of 252)
What is the sentiment on the street regarding Catalyst Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CPRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CPRX before you decide to make any investment.
Click here for chart >>
Thanks for reading!